BR112018070603A2 - formulações líquidas de fosfaplatina - Google Patents

formulações líquidas de fosfaplatina

Info

Publication number
BR112018070603A2
BR112018070603A2 BR112018070603A BR112018070603A BR112018070603A2 BR 112018070603 A2 BR112018070603 A2 BR 112018070603A2 BR 112018070603 A BR112018070603 A BR 112018070603A BR 112018070603 A BR112018070603 A BR 112018070603A BR 112018070603 A2 BR112018070603 A2 BR 112018070603A2
Authority
BR
Brazil
Prior art keywords
liquid formulations
phosfaplatin
pyrodach
buffered
preparation
Prior art date
Application number
BR112018070603A
Other languages
English (en)
Inventor
Ames Tyler
d luke Wayne
Original Assignee
Phosplatin Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phosplatin Therapeutics Llc filed Critical Phosplatin Therapeutics Llc
Publication of BR112018070603A2 publication Critical patent/BR112018070603A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

trata-se de composições farmacêuticas de compostos de fosfaplatina, em particular, formulações líquidas estáveis tamponadas de pirodach-2 prontas para o uso no tratamento de vários cânceres, e métodos de preparação.
BR112018070603A 2016-04-06 2017-04-05 formulações líquidas de fosfaplatina BR112018070603A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319047P 2016-04-06 2016-04-06
PCT/US2017/026139 WO2017176880A1 (en) 2016-04-06 2017-04-05 Phosphaplatin liquid formulations

Publications (1)

Publication Number Publication Date
BR112018070603A2 true BR112018070603A2 (pt) 2019-02-05

Family

ID=60000715

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018070603A BR112018070603A2 (pt) 2016-04-06 2017-04-05 formulações líquidas de fosfaplatina

Country Status (18)

Country Link
US (1) US11154529B2 (pt)
EP (1) EP3439650A4 (pt)
JP (2) JP2019510831A (pt)
KR (1) KR102419247B1 (pt)
CN (1) CN109310663B (pt)
AU (1) AU2017246883B2 (pt)
BR (1) BR112018070603A2 (pt)
CA (1) CA3020166A1 (pt)
CL (1) CL2018002848A1 (pt)
CO (1) CO2018011420A2 (pt)
EA (1) EA039525B1 (pt)
IL (1) IL262066A (pt)
MX (1) MX2018012223A (pt)
PH (1) PH12018502139A1 (pt)
SG (1) SG11201808717QA (pt)
TW (1) TWI798175B (pt)
WO (1) WO2017176880A1 (pt)
ZA (1) ZA201806530B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110381952B (zh) * 2017-01-06 2023-10-20 弗斯普拉廷治疗有限公司 作为治疗剂用于治疗骨癌或血癌的磷铂化合物
WO2022087173A1 (en) * 2020-10-20 2022-04-28 Phosplatin Therapeutics Inc. Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000858A2 (en) * 2003-06-27 2005-01-06 Akira Odani Bisphosphonate complexes
EP2575802B1 (en) * 2010-06-04 2016-11-16 Ohio University Phosphaplatins and their use for treatment of cancers
WO2012096722A1 (en) 2011-01-12 2012-07-19 Ohio University Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof
CA2851254A1 (en) * 2011-10-05 2013-04-11 Shadi MOGHADDAS Efficient processes for large scale preparation of phophaplatins antitumor agents
US9012669B2 (en) * 2011-10-05 2015-04-21 The University Of Houston System Efficient processes for large scale preparation of phosphaplatins antitumor agents
ES2751668T3 (es) * 2012-05-24 2020-04-01 Phosplatin Therapeutics Llc Método de purificación para compuestos de fosfaplatino

Also Published As

Publication number Publication date
CN109310663B (zh) 2022-05-31
ZA201806530B (en) 2019-07-31
KR102419247B1 (ko) 2022-07-11
CO2018011420A2 (es) 2019-02-08
US11154529B2 (en) 2021-10-26
WO2017176880A1 (en) 2017-10-12
PH12018502139A1 (en) 2019-09-23
KR20180133889A (ko) 2018-12-17
EP3439650A4 (en) 2019-12-11
US20200323810A1 (en) 2020-10-15
JP2023014110A (ja) 2023-01-26
EP3439650A1 (en) 2019-02-13
CL2018002848A1 (es) 2018-12-21
CA3020166A1 (en) 2017-10-12
JP2019510831A (ja) 2019-04-18
AU2017246883A1 (en) 2018-11-08
EA201892157A1 (ru) 2019-04-30
AU2017246883B2 (en) 2023-02-09
EA039525B1 (ru) 2022-02-07
TWI798175B (zh) 2023-04-11
MX2018012223A (es) 2019-05-30
SG11201808717QA (en) 2018-11-29
IL262066A (en) 2018-11-29
CN109310663A (zh) 2019-02-05
TW201737920A (zh) 2017-11-01

Similar Documents

Publication Publication Date Title
CY1121907T1 (el) Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων
CO2018004315A2 (es) Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
BR112015032736A2 (pt) inibidores de bromodomínio cristalino
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
BR112018011319A2 (pt) novos anticorpos anti-claudina e métodos de uso
CL2015002897A1 (es) Inhibidores de bace1
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
BR112016027043A2 (pt) Combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
BR112017003219A2 (pt) formulação de acetato de abiraterona e métodos de uso
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2017002680A1 (es) Construcciones de calicheamicina y sus métodos de uso
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B25D Requested change of name of applicant approved

Owner name: PHOSPLATIN THERAPEUTICS INC. (US)

B25D Requested change of name of applicant approved

Owner name: PROMONTORY THERAPEUTICS INC. (US)